Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy

European Journal of Cancer

Volumn 50, Issue 4, 2014, Pages 698-705

  Lee, Soo Youn ^a   Im, Seock Ah ^b   Park, Yeon Hee ^a   Woo, Sook Young ^c   Kim, Seonwoo ^c   Choi, Moon Ki ^a   Chang, Wonjin ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Breast cancer; Gemcitabine; Paclitaxel; Pharmacogenomics

Indexed keywords

BREAST CANCER; GEMCITABINE; PACLITAXEL; PHARMACOGENOMICS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84894040367     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.11.028     Document Type: Article

References (27)

1. Y.H. Park, K.H. Jung, and S.A. Im et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02 J Clin Oncol 31 14 2013 1732 1739
2. K. Kiyotani, S. Uno, and T. Mushiroda et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy Pharmacogenet Genomics 22 2012 229 235
3. P. Cano-Soldado, and M. Pastor-Anglada Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition Med Res Rev 32 2012 428 457
4. J.A. Baker, E.R. Wickremsinhe, and C.H. Li et al. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase Drug Metab Dispos 41 2013 541 545
5. H.I. Woo, K.K. Kim, and H. Choi et al. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine Pharmacogenomics 13 2012 1023 1035
6. L. Yu, D. Shi, L. Ma, Q. Zhou, and S. Zeng Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide, and ibuprofen enantiomers in vitro Biopharm Drug Dispos 34 5 2013 278 287
7. D.L. Hertz, A.A. Motsinger-Reif, and A. Drobish et al. CYP2C8â̂ - 3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel Breast Cancer Res Treat 134 2012 401 410
8. T.M. Bosch, A.D. Huitema, and V.D. Doodeman et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 2006 5786 5793
9. H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin Cancer Res 12 2006 854 859
10. H. Chang, S.Y. Rha, and H.C. Jeung et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients Ann Oncol 20 2009 272 277
11. H. Chang, S.Y. Rha, and H.C. Jeung et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy Oncol Rep 23 2010 271 278
12. M. Pastor-Anglada, P. Cano-Soldado, E. Errasti-Murugarren, and F.J. Casado SLC28 genes and concentrative nucleoside transporter (CNT) proteins Xenobiotica 38 2008 972 994
13. J.W. Kim, J.H. Kim, and S.A. Im et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy Oncology 83 2012 218 227
14. A.K. Mitra, M.N. Kirstein, and A. Khatri et al. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors Pharmacogenomics 13 2012 1009 1021
15. R. Marechal, J.B. Bachet, and J.R. Mackey et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma Gastroenterology 143 664-74 2012 e1 e6
16. F. Innocenti, K. Owzar, and N.L. Cox et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Clin Cancer Res 18 2012 577 584
17. J. Zhou, Z. Chen, and A. Malysa et al. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy PLoS One 8 2013 e58091
18. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sorensen Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial Ann Oncol 24 2013 309 314
19. S.T. Lee, S. Ryu, and S.R. Kim et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response J Clin Psychopharmacol 32 2012 441 448
20. H.H. Won, J. Lee, and J.O. Park et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients Cancer 118 2012 2828 2836
21. K.S. Albain, S.M. Nag, and G. Calderillo-Ruiz et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 2008 3950 3957
22. T. Okazaki, M. Javle, M. Tanaka, J.L. Abbruzzese, and D. Li Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity Clin Cancer Res 16 2010 320 329
23. L. Li, D.J. Schaid, and B.L. Fridley et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer Pharmacogenet Genomics 22 2012 105 116
24. L.P. Jordheim, P. Seve, O. Tredan, and C. Dumontet The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer Lancet Oncol 12 2011 693 702
25. N. Erculj, V. Kovac, J. Hmeljak, A. Franko, M. Dodic-Fikfak, and V. Dolzan The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma Pharmacogenet Genomics 22 2012 58 68
26. J. Rodriguez, V. Boni, and A. Hernandez et al. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy Eur J Cancer 47 2011 839 847
27. S.Y. Rha, H.C. Jeung, and Y.H. Choi et al. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients Oncologist 12 2007 622 630